David A. Scheinberg, MD, PhD

Chair, Experimental Therapeutics Center; Vincent Astor Chair
David A. Scheinberg, MD, PhD -- Chair, Experimental Therapeutics Center; Vincent Astor Chair

Dr. Scheinberg is a physician-scientist who specializes in the care of patients with leukemia and is also investigating new therapeutic approaches to cancer, both in the clinic and in the laboratory. His research is focused on discovering and developing novel, specific immunotherapeutic agents. These include monoclonal antibodies that target the cell surface of cancers, targeted radiopharmaceuticals that deliver radioactive particles including alpha particles or alpha particle nanogenerators, targeted nanodevices that selectively kill cancer cells, and therapeutic vaccines that target the oncogene products that cause the cancers.

Eight different therapeutic agents developed by Dr. Scheinberg in his laboratory have reached human clinical trials, including the first humanized antibodies to treat acute leukemia, the first targeted alpha particle therapies and alpha generators, and the first tumor-specific fusion oncogene product vaccines. His laboratory is also investigating cellular resistance mechanisms to these agents. Dr. Scheinberg has published more than 250 papers, chapters, and books in these fields.

Clinical Expertise

Acute and Chronic Leukemias; Immunotherapy; Monoclonal Antibodies; Cancer Vaccines

Languages Spoken

MD, PhD, The Johns Hopkins School of Medicine


The New York Hospital/Cornell Medical Center


Memorial Sloan Kettering Cancer Center

Board Certifications

Internal Medicine; Medical Oncology

Publications by David A. Scheinberg
Visit PubMed for full listing of David A. Scheinberg journal articles
Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.
View David A. Scheinberg's laboratory research.